Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The guidelines provide a general definition of remission after resection of an ACTH-producing corticotroph tumor as morning serum cortisol levels <5 μg/dL (<138 nmol/L) or UFC <28-56 nmol/d (<10-20 μg/d) within 7 days of tumor resection (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Steroidogenesis inhibitors work by inhibiting one or more enzymes involved in steroidogenesis, decreasing cortisol and other steroid hormone production (37, 38).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Available medical therapies currently used in clinical practice to treat CS include medications from 3 classes: pituitary-directed therapies (for pituitary CD only), steroidogenesis inhibitors, and glucocorticoid receptor antagonists (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“In patients with CS, surgical resection of the causative lesion(s) is the first-line treatment option regardless of etiology.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Pituitary-directed therapies, including pasireotide (US/EU/Canada) and cabergoline (off-label use only), inhibit pituitary ACTH production and, in some cases, ectopic ACTH secretion from neuroendocrine tumors, thereby reducing downstream cortisol secretion (37, 128).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–213 of 213
Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome
Engelhardt, D., Jacob, K., & Doerr, H. G. (1989) · Journal of Molecular Medicine · doi:10.1007/bf01717326 · Cited by 27
KETOCONAZOLE AND PLASMA AND URINE STEROID LEVELS IN CUSHING'S DISEASE
Mortimer, R. H., Cannell, G. R., Thew, C. M., & Galligan, J. P. (1991) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1991.tb01492.x · Cited by 23
Thyroid function in children with Cushing's disease before and after transsphenoidal surgery
Stratakis, C. A., Mastorakas, G., Magiakou, M.-A., Papavasiliou, E., Oldfield, E. H., & Chrousos, G. P. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70041-6 · Cited by 21
Klopfenstein, B. J., Purnell, J. Q., Brandon, D. D., Isabelle, L. M., & DeBarber, A. E. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.12.008 · Cited by 19
Diagnosis of Cure in Cushing's Syndrome: Lessons from Long-Term Follow-Up
Barahona, M. J., Resmini, E., Sucunza, N., & Webb, S. M. (2010) · Frontiers of hormone research · doi:10.1159/000318505 · Cited by 18
Neurosurgical treatment of Cushing disease
Sheth, S. A., Bourne, S. K., Tritos, N. A., & Swearingen, B. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.006 · Cited by 15 · cited 1×
“Patients with presumed occult EAS may in fact have CD and thus should be regularly examined for the emergence of a pituitary tumor (94).”
Background[Short term effects of ketoconazole in Cushing's syndrome].
Cerdas, S., BILLAUD, L., Guilhaume, B., Laudat, M. H., BERTAGNA, X. Y., & LUTON, J. P. (1989) · PubMed · Cited by 15
[Long-term treatment of Cushing's disease using ketoconazole. Possibility of therapeutic escape].
Diop, S. N., Warnet, A., Duet, M., Firmin, C., Mosse, A., & Lubetzki, J. (1989) · PubMed · Cited by 15
Guanà, R., Gesmundo, R., Morino, M., Matarazzo, P., Pucci, A., Pasini, B., Lala, R., Fiore, L., Repici, M., & Canavese, F. (2010) · European Journal of Pediatric Surgery · doi:10.1055/s-0029-1243203 · Cited by 14
Kumorowicz-Czoch, M., Doleżal-Ołtarzewska, K., Roztoczyńska, D., Chrupek, M., Prokurat, A. I., Drabik, G., & Starzyk, J. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.002 · Cited by 14
Mukherjee, A., Murray, R. D., Teasdale, G. M., & Shalet, S. M. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02004.x · Cited by 11
Kalgikar, A. M., Chandratreya, S. A., Goel, A. H., Shrivastava, M., Limaye, U. S., Karvat, A., Shah, N. S., & Menon, P. S. (2005) · PubMed · Cited by 8
Type 2 diabetes identified in pregnancy secondary to Cushing's syndrome
Schiemer, R., Latibeaudiere, M., Close, C. F., & Fox, R. (2011) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2011.584645 · Cited by 7
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Self-citationCarey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2807-2831
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4525003
- OpenAlex
- W2127952551
- Semantic Scholar
- 4d26bfff9a2f2ea132ea661d03d84dc8b2293884
- Cited by
- 1,270
- References
- 213
- Citations by year
- 2026: 99 · 2025: 120 · 2024: 104 · 2023: 117 · 2022: 148 · 2021: 169 · 2020: 116 · 2019: 112 · 2018: 116 · 2017: 83 · 2016: 75 · 2015: 6
- FWCI
- 80.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- Cushing's syndrome, hypercortisolism, surgical resection, bilateral adrenalectomy, radiotherapy, corticotropinoma, comorbidity management, treatment selection
- MeSH terms
- Adrenal Gland Neoplasms, Adrenalectomy, Cushing Syndrome, Endocrinology, Humans, Patient Care Planning, Pituitary Neoplasms, Recurrence, Remission Induction, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.